OPTIMIZED MONOCLONAL ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR (TFPI)

• Main Authors: PETER SCHOLZ, CHRISTIAN VOTSMEIER, JUNLIANG PAN, SUSANNE STEINIG, WANG ZHUOZHI, JAN TEBBE, JOANNA GRUDZINSKA, JOERG BIRKENFELD, NINA WOBST, SIMONE BRUECKNER
• Format: Patent
• Language: English; Japanese
• Published: 13.06.2019
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

To provide isolated monoclonal antibodies and fragments thereof that bind the human tissue factor pathway inhibitor (TFPI).SOLUTION: An isolated human monoclonal antibody that binds specifically to the human tissue factor pathway inhibitor (TFPI) comprises: a human heavy chain comprising a CDR1 region, a CDR2 region and a CDR3 region that comprise specific amino acid substitutions; and a human light chain comprising a CDR1 region, a CDR2 region and a CDR3 region that comprise specific amino acid substitutions.SELECTED DRAWING: None 【課題】ヒト組織因子経路インヒビター（ＴＦＰＩ）に結合する単離されたモノクローナル抗体およびそれらのフラグメントを提供する。【解決手段】特定のアミノ酸置換を有する、ＣＤＲ１領域、ＣＤＲ２領域、ＣＤＲ３領域を含むヒト重鎖、及び特定のアミノ酸置換を有する、ＣＤＲ１領域、ＣＤＲ２領域、ＣＤＲ３領域を含むヒト軽鎖、を含む、ヒト組織因子経路インヒビター（ＴＦＰＩ）に特異的に結合する単離されたヒトモノクローナル抗体。【選択図】なし